- Recommendation ID
Further research on selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma in the form of prospective studies, including randomised controlled trials, should address patient selection, quality-of-life outcomes and overall survival. Patient selection for the research studies should be done by a
multidisciplinary team. The procedure should only be done in specialist centres by clinicians trained and experienced in managing cholangiocarcinoma.
- Any explanatory notes
Current evidence on the safety of selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma shows that there are well-recognised, serious but rare safety concerns. Evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.
Source guidance details
- Comes from guidance
- Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma
- Date issued
- October 2018
|Is this a recommendation for the use of a technology only in the context of research?||Yes|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|